메뉴 건너뛰기




Volumn 33, Issue 1, 2015, Pages 101-114

Huntington Disease: Pathogenesis and Treatment

Author keywords

Chorea; Huntingtin; Huntington; Neurodegeneration; Pathogenesis; Polyglutamine; Striatum; Treatment

Indexed keywords

AMANTADINE; AMFEBUTAMONE; ANTICONVULSIVE AGENT; BUSPIRONE; CARBAMAZEPINE; DONEPEZIL; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; HUNTINGTIN; LEVODOPA; MEMANTINE; MOOD STABILIZER; OLANZAPINE; RISPERIDONE; RIVASTIGMINE; SEROTONIN UPTAKE INHIBITOR; TETRABENAZINE; VALPROIC ACID; HTT PROTEIN, HUMAN; NERVE PROTEIN;

EID: 84918574081     PISSN: 07338619     EISSN: 15579875     Source Type: Journal    
DOI: 10.1016/j.ncl.2014.09.003     Document Type: Review
Times cited : (177)

References (91)
  • 1
    • 0027468861 scopus 로고
    • Duration of illness in Huntington's disease is not related to age at onset
    • Roos R, Hermans J, Vegtervandervlis M, et al. Duration of illness in Huntington's disease is not related to age at onset. J Neurol Neurosurg Psychiatr 1993;56(1): 98-100.
    • (1993) J Neurol Neurosurg Psychiatr , vol.56 , Issue.1 , pp. 98-100
    • Roos, R.1    Hermans, J.2    Vegtervandervlis, M.3
  • 2
    • 84884594132 scopus 로고    scopus 로고
    • Prevalence of adult Huntington's disease in the UK based on diagnoses recorded in general practice records
    • Evans SJ, Douglas I, Rawlins MD, et al. Prevalence of adult Huntington's disease in the UK based on diagnoses recorded in general practice records. J Neurol Neurosurg Psychiatr 2013;84(10):1156-60.
    • (2013) J Neurol Neurosurg Psychiatr , vol.84 , Issue.10 , pp. 1156-1160
    • Evans, S.J.1    Douglas, I.2    Rawlins, M.D.3
  • 3
    • 84892932050 scopus 로고    scopus 로고
    • Multisource ascertainment of Huntington disease in Canada: prevalence and population at risk
    • Fisher ER, Hayden MR. Multisource ascertainment of Huntington disease in Canada: prevalence and population at risk. Mov Disord 2014;29(1):105-14.
    • (2014) Mov Disord , vol.29 , Issue.1 , pp. 105-114
    • Fisher, E.R.1    Hayden, M.R.2
  • 4
    • 0027480960 scopus 로고
    • A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes
    • Macdonald ME, Ambrose CM, Duyao MP, et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993;72(6):971-83.
    • (1993) Cell , vol.72 , Issue.6 , pp. 971-983
    • Macdonald, M.E.1    Ambrose, C.M.2    Duyao, M.P.3
  • 5
    • 0028316870 scopus 로고
    • A worldwide study of the Huntington's disease mutation: the sensitivity and specificity of measuring CAG repeats
    • Kremer B, Goldberg P, Andrew SE, et al. A worldwide study of the Huntington's disease mutation: the sensitivity and specificity of measuring CAG repeats. N Engl J Med 1994;330(20):1401-6.
    • (1994) N Engl J Med , vol.330 , Issue.20 , pp. 1401-1406
    • Kremer, B.1    Goldberg, P.2    Andrew, S.E.3
  • 6
    • 80052769417 scopus 로고    scopus 로고
    • Exploring the correlates of intermediate CAG repeats in Huntington disease
    • Ha AD, Jankovic J. Exploring the correlates of intermediate CAG repeats in Huntington disease. Postgrad Med 2011;123(5):116-21.
    • (2011) Postgrad Med , vol.123 , Issue.5 , pp. 116-121
    • Ha, A.D.1    Jankovic, J.2
  • 7
    • 0034780024 scopus 로고    scopus 로고
    • High incidence rate and absent family histories in one quarter of patients newly diagnosed with Huntington disease in British Columbia
    • Almqvist EW, Elterman DS, MacLeod PM, et al. High incidence rate and absent family histories in one quarter of patients newly diagnosed with Huntington disease in British Columbia. Clin Genet 2001;60(3):198-205.
    • (2001) Clin Genet , vol.60 , Issue.3 , pp. 198-205
    • Almqvist, E.W.1    Elterman, D.S.2    MacLeod, P.M.3
  • 8
    • 0035128291 scopus 로고    scopus 로고
    • Measurement of mutational flow implies both a high new-mutation rate for Huntington disease and substantial underascertainment of late-onset cases
    • Falush D, Almqvist EW, Brinkmann RR, et al. Measurement of mutational flow implies both a high new-mutation rate for Huntington disease and substantial underascertainment of late-onset cases. Am J Hum Genet 2001;68(2):373-85.
    • (2001) Am J Hum Genet , vol.68 , Issue.2 , pp. 373-385
    • Falush, D.1    Almqvist, E.W.2    Brinkmann, R.R.3
  • 9
    • 0023112148 scopus 로고
    • Saccades in Huntington's disease: initiation defects and distractibility
    • Lasker AG, Zee DS, Hain TC, et al. Saccades in Huntington's disease: initiation defects and distractibility. Neurology 1987;37(3):364-70.
    • (1987) Neurology , vol.37 , Issue.3 , pp. 364-370
    • Lasker, A.G.1    Zee, D.S.2    Hain, T.C.3
  • 10
    • 0028919687 scopus 로고
    • Functional decline in Huntington's disease
    • Feigin A, Kieburtz K, Bordwell K, et al. Functional decline in Huntington's disease. Mov Disord 1995;10(2):211-4.
    • (1995) Mov Disord , vol.10 , Issue.2 , pp. 211-214
    • Feigin, A.1    Kieburtz, K.2    Bordwell, K.3
  • 11
    • 84885649254 scopus 로고    scopus 로고
    • Cognitive decline in prodromal Huntington disease: implications for clinical trials
    • Paulsen JS, Smith MM, Long JD, PREDICT HD Investigators, Huntington Study Group. Cognitive decline in prodromal Huntington disease: implications for clinical trials. J Neurol Neurosurg Psychiatr 2013;84(11):1233-9.
    • (2013) J Neurol Neurosurg Psychiatr , vol.84 , Issue.11 , pp. 1233-1239
    • Paulsen, J.S.1    Smith, M.M.2    Long, J.D.3
  • 12
    • 0032815395 scopus 로고    scopus 로고
    • The disparate effects of Alzheimer's disease and Huntington's disease on semantic memory
    • Rohrer D, Salmon DP, Wixted JT, et al. The disparate effects of Alzheimer's disease and Huntington's disease on semantic memory. Neuropsychology 1999; 13(3):381-8.
    • (1999) Neuropsychology , vol.13 , Issue.3 , pp. 381-388
    • Rohrer, D.1    Salmon, D.P.2    Wixted, J.T.3
  • 13
    • 0029043634 scopus 로고
    • Distinct cognitive profiles of cortical and subcortical dementia in advanced illness
    • Paulsen JS, Butters N, Sadek JR, et al. Distinct cognitive profiles of cortical and subcortical dementia in advanced illness. Neurology 1995;45(5):951-6.
    • (1995) Neurology , vol.45 , Issue.5 , pp. 951-956
    • Paulsen, J.S.1    Butters, N.2    Sadek, J.R.3
  • 14
    • 34248560852 scopus 로고    scopus 로고
    • Patients with Huntington's disease have impaired awareness of cognitive, emotional, and functional abilities
    • Hoth KF, Paulsen JS, Moser DJ, et al. Patients with Huntington's disease have impaired awareness of cognitive, emotional, and functional abilities. J Clin Exp Neuropsychol 2007;29(4):365-76.
    • (2007) J Clin Exp Neuropsychol , vol.29 , Issue.4 , pp. 365-376
    • Hoth, K.F.1    Paulsen, J.S.2    Moser, D.J.3
  • 16
    • 0020633043 scopus 로고
    • Psychiatric syndromes in Huntington's disease
    • Caine ED, Shoulson I. Psychiatric syndromes in Huntington's disease. Am J Psychiatry 1983;140(6):728-33.
    • (1983) Am J Psychiatry , vol.140 , Issue.6 , pp. 728-733
    • Caine, E.D.1    Shoulson, I.2
  • 17
    • 36549036813 scopus 로고    scopus 로고
    • Psychiatric symptoms in Huntington's disease before diagnosis: the predict-HD study
    • Duff K, Paulsen JS, Beglinger LJ, et al, Predict-HD Investigators. Psychiatric symptoms in Huntington's disease before diagnosis: the predict-HD study. Biol Psychiatry 2007;62(12):1341-6.
    • (2007) Biol Psychiatry , vol.62 , Issue.12 , pp. 1341-1346
    • Duff, K.1    Paulsen, J.S.2    Beglinger, L.J.3
  • 18
    • 0036714830 scopus 로고    scopus 로고
    • Longitudinal personality changes among presymptomatic Huntington disease gene carriers
    • Kirkwood SC, Siemers E, Viken R, et al. Longitudinal personality changes among presymptomatic Huntington disease gene carriers. Neuropsychiatry Neuropsychol Behav Neurol 2002;15(3):192-7.
    • (2002) Neuropsychiatry Neuropsychol Behav Neurol , vol.15 , Issue.3 , pp. 192-197
    • Kirkwood, S.C.1    Siemers, E.2    Viken, R.3
  • 19
    • 0036829059 scopus 로고    scopus 로고
    • Evaluation of psychological symptoms among presymptomatic HD gene carriers as measured by selected MMPI scales
    • Kirkwood SC, Siemers E, Viken RJ, et al. Evaluation of psychological symptoms among presymptomatic HD gene carriers as measured by selected MMPI scales. J Psychiatr Res 2002;36(6):377-82.
    • (2002) J Psychiatr Res , vol.36 , Issue.6 , pp. 377-382
    • Kirkwood, S.C.1    Siemers, E.2    Viken, R.J.3
  • 21
    • 0027134654 scopus 로고
    • Risk-factors for suicide in Huntington's disease: a retrospective case-controlled study
    • Lipe H, Schultz A, Bird TD. Risk-factors for suicide in Huntington's disease: a retrospective case-controlled study. Am J Med Genet 1993;48(4):231-3.
    • (1993) Am J Med Genet , vol.48 , Issue.4 , pp. 231-233
    • Lipe, H.1    Schultz, A.2    Bird, T.D.3
  • 22
    • 0033358526 scopus 로고    scopus 로고
    • A worldwide assessment of the frequency of suicide, suicide attempts, or psychiatric hospitalization after predictive testing for Huntington disease
    • Almqvist EW, Bloch M, Brinkman R, et al, Int Huntington Dis Collaborative Group. A worldwide assessment of the frequency of suicide, suicide attempts, or psychiatric hospitalization after predictive testing for Huntington disease. Am J Hum Genet 1999;64(5):1293-304.
    • (1999) Am J Hum Genet , vol.64 , Issue.5 , pp. 1293-1304
    • Almqvist, E.W.1    Bloch, M.2    Brinkman, R.3
  • 24
    • 79952740327 scopus 로고    scopus 로고
    • Longitudinal change in regional brain volumes in prodromal Huntington disease
    • Aylward EH, Nopoulos PC, Ross CA, et al. Longitudinal change in regional brain volumes in prodromal Huntington disease. J Neurol Neurosurg Psychiatr 2011; 82(4):405-10.
    • (2011) J Neurol Neurosurg Psychiatr , vol.82 , Issue.4 , pp. 405-410
    • Aylward, E.H.1    Nopoulos, P.C.2    Ross, C.A.3
  • 25
    • 84879032355 scopus 로고    scopus 로고
    • Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data
    • Tabrizi SJ, Scahill RI, Owen G, et al. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol 2013;12(7):637-49.
    • (2013) Lancet Neurol , vol.12 , Issue.7 , pp. 637-649
    • Tabrizi, S.J.1    Scahill, R.I.2    Owen, G.3
  • 26
    • 68249113963 scopus 로고    scopus 로고
    • Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: Cross-sectional analysis of baseline data
    • Tabrizi SJ, Langbehn DR, Leavitt BR, et al. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: Cross-sectional analysis of baseline data. Lancet Neurol 2009;8(9):791-801.
    • (2009) Lancet Neurol , vol.8 , Issue.9 , pp. 791-801
    • Tabrizi, S.J.1    Langbehn, D.R.2    Leavitt, B.R.3
  • 27
    • 0037066115 scopus 로고    scopus 로고
    • Regional and progressive thinning of the cortical ribbon in Huntington's disease
    • Rosas HD, Liu AK, Hersch S, et al. Regional and progressive thinning of the cortical ribbon in Huntington's disease. Neurology 2002;58(5):695-701.
    • (2002) Neurology , vol.58 , Issue.5 , pp. 695-701
    • Rosas, H.D.1    Liu, A.K.2    Hersch, S.3
  • 28
    • 24644479046 scopus 로고    scopus 로고
    • Regional cortical thinning in preclinical Huntington disease and its relationship to cognition
    • Rosas HD, Hevelone ND, Zaleta AK, et al. Regional cortical thinning in preclinical Huntington disease and its relationship to cognition. Neurology 2005;65(5): 745-7.
    • (2005) Neurology , vol.65 , Issue.5 , pp. 745-747
    • Rosas, H.D.1    Hevelone, N.D.2    Zaleta, A.K.3
  • 29
    • 0037069280 scopus 로고    scopus 로고
    • Weight loss in early stage of Huntington's disease
    • Djousse L, Knowlton B, Cupples L, et al. Weight loss in early stage of Huntington's disease. Neurology 2002;59(9):1325-30.
    • (2002) Neurology , vol.59 , Issue.9 , pp. 1325-1330
    • Djousse, L.1    Knowlton, B.2    Cupples, L.3
  • 30
    • 84866082207 scopus 로고    scopus 로고
    • Measures of growth in children at risk for Huntington disease
    • Lee JK, Mathews K, Schlaggar B, et al. Measures of growth in children at risk for Huntington disease. Neurology 2012;79(7):668-74.
    • (2012) Neurology , vol.79 , Issue.7 , pp. 668-674
    • Lee, J.K.1    Mathews, K.2    Schlaggar, B.3
  • 31
    • 78650699846 scopus 로고    scopus 로고
    • Smaller intracranial volume in prodromal Huntington's disease: evidence for abnormal neurodevelopment
    • Nopoulos PC, Aylward EH, Ross CA, et al. Smaller intracranial volume in prodromal Huntington's disease: evidence for abnormal neurodevelopment. Brain 2011; 134:137-42.
    • (2011) Brain , vol.134 , pp. 137-142
    • Nopoulos, P.C.1    Aylward, E.H.2    Ross, C.A.3
  • 32
  • 33
    • 0029895292 scopus 로고    scopus 로고
    • Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease
    • Weeks RA, Piccini P, Harding AE, et al. Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease. Ann Neurol 1996;40(1):49-54.
    • (1996) Ann Neurol , vol.40 , Issue.1 , pp. 49-54
    • Weeks, R.A.1    Piccini, P.2    Harding, A.E.3
  • 34
    • 25444467559 scopus 로고    scopus 로고
    • Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease
    • van Oostrom JC, Maguire RP, Verschuuren-Bemelmans CC, et al. Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease. Neurology 2005;65(6):941-3.
    • (2005) Neurology , vol.65 , Issue.6 , pp. 941-943
    • van Oostrom, J.C.1    Maguire, R.P.2    Verschuuren-Bemelmans, C.C.3
  • 35
    • 0030897476 scopus 로고    scopus 로고
    • PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease
    • Ginovart N, Lundin A, Farde L, et al. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. Brain 1997;120:503-14.
    • (1997) Brain , vol.120 , pp. 503-514
    • Ginovart, N.1    Lundin, A.2    Farde, L.3
  • 36
    • 0037075624 scopus 로고    scopus 로고
    • Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease
    • Zeron MM, Hansson O, Chen NS, et al. Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 2002;33(6):849-60.
    • (2002) Neuron , vol.33 , Issue.6 , pp. 849-860
    • Zeron, M.M.1    Hansson, O.2    Chen, N.S.3
  • 37
    • 63849154126 scopus 로고    scopus 로고
    • In vivo evidence for NMDA receptormediated excitotoxicity in a murine genetic model of Huntington disease
    • Heng MY, Detloff PJ, Wang PL, et al. In vivo evidence for NMDA receptormediated excitotoxicity in a murine genetic model of Huntington disease. J Neurosci 2009;29(10):3200-5.
    • (2009) J Neurosci , vol.29 , Issue.10 , pp. 3200-3205
    • Heng, M.Y.1    Detloff, P.J.2    Wang, P.L.3
  • 38
    • 34047100940 scopus 로고    scopus 로고
    • N-methyl-D-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease
    • Fan MMY, Raymond LA. N-methyl-D-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease. Prog Neurobiol 2007;81(5-6):272-93.
    • (2007) Prog Neurobiol , vol.81 , Issue.5-6 , pp. 272-293
    • Fan, M.M.Y.1    Raymond, L.A.2
  • 39
    • 0023227209 scopus 로고
    • Sparing of acetylcholinesterasecontaining striatal neurons in Huntington's disease
    • Ferrante RJ, Beal MF, Kowall NW, et al. Sparing of acetylcholinesterasecontaining striatal neurons in Huntington's disease. Brain Res 1987;411(1):162-6.
    • (1987) Brain Res , vol.411 , Issue.1 , pp. 162-166
    • Ferrante, R.J.1    Beal, M.F.2    Kowall, N.W.3
  • 40
    • 84886442235 scopus 로고    scopus 로고
    • Striatal parvalbuminergic neurons are lost in Huntington's disease: implications for dystonia
    • Reiner A, Shelby E, Wang H, et al. Striatal parvalbuminergic neurons are lost in Huntington's disease: implications for dystonia. Mov Disord 2013;28(12):1691-9.
    • (2013) Mov Disord , vol.28 , Issue.12 , pp. 1691-1699
    • Reiner, A.1    Shelby, E.2    Wang, H.3
  • 41
    • 2942625910 scopus 로고    scopus 로고
    • Differential loss of striatal projection systems in Huntington's disease: a quantitative immunohistochemical study
    • Deng YP, Albin RL, Penney JB, et al. Differential loss of striatal projection systems in Huntington's disease: a quantitative immunohistochemical study. J Chem Neuroanat 2004;27(3):143-64.
    • (2004) J Chem Neuroanat , vol.27 , Issue.3 , pp. 143-164
    • Deng, Y.P.1    Albin, R.L.2    Penney, J.B.3
  • 42
    • 0026717486 scopus 로고
    • Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington's disease
    • Albin RL, Reiner A, Anderson KD, et al. Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington's disease. Ann Neurol 1992; 31(4):425-30.
    • (1992) Ann Neurol , vol.31 , Issue.4 , pp. 425-430
    • Albin, R.L.1    Reiner, A.2    Anderson, K.D.3
  • 43
    • 0001589776 scopus 로고
    • Differential loss of striatal projection neurons in Huntington disease
    • Reiner A, Albin RL, Anderson KD, et al. Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci U S A 1988;85(15):5733-7.
    • (1988) Proc Natl Acad Sci U S A , vol.85 , Issue.15 , pp. 5733-5737
    • Reiner, A.1    Albin, R.L.2    Anderson, K.D.3
  • 44
    • 0025276132 scopus 로고
    • Striatal and nigral neuron subpopulations in rigid Huntington's disease: implications for the functional-anatomy of chorea and rigidity-akinesia
    • Albin RL, Reiner A, Anderson KD, et al. Striatal and nigral neuron subpopulations in rigid Huntington's disease: implications for the functional-anatomy of chorea and rigidity-akinesia. Ann Neurol 1990;27(4):357-65.
    • (1990) Ann Neurol , vol.27 , Issue.4 , pp. 357-365
    • Albin, R.L.1    Reiner, A.2    Anderson, K.D.3
  • 45
    • 33845880405 scopus 로고    scopus 로고
    • Striosomes and mood dysfunction in Huntington's disease
    • Tippett LJ, Waldvogel HJ, Thomas SJ, et al. Striosomes and mood dysfunction in Huntington's disease. Brain 2007;130:206-21.
    • (2007) Brain , vol.130 , pp. 206-221
    • Tippett, L.J.1    Waldvogel, H.J.2    Thomas, S.J.3
  • 46
    • 0027377151 scopus 로고
    • Correlation between the onset age of Huntington's disease and length of the trinucleotide repeat in it-15
    • Stine OC, Pleasant N, Franz ML, et al. Correlation between the onset age of Huntington's disease and length of the trinucleotide repeat in it-15. Hum Mol Genet 1993;2(10):1547-9.
    • (1993) Hum Mol Genet , vol.2 , Issue.10 , pp. 1547-1549
    • Stine, O.C.1    Pleasant, N.2    Franz, M.L.3
  • 47
    • 0028099274 scopus 로고
    • Trinucleotide repeat length and progression of illness in Huntington's disease
    • Kieburtz K, Macdonald M, Shih C, et al. Trinucleotide repeat length and progression of illness in Huntington's disease. J Med Genet 1994;31(11):872-4.
    • (1994) J Med Genet , vol.31 , Issue.11 , pp. 872-874
    • Kieburtz, K.1    Macdonald, M.2    Shih, C.3
  • 48
    • 0027176364 scopus 로고
    • The relationship between trinucleotide (CAG) repeat length and clinical-features of Huntington's disease
    • Andrew SE, Goldberg YP, Kremer B, et al. The relationship between trinucleotide (CAG) repeat length and clinical-features of Huntington's disease. Nat Genet 1993;4(4):398-403.
    • (1993) Nat Genet , vol.4 , Issue.4 , pp. 398-403
    • Andrew, S.E.1    Goldberg, Y.P.2    Kremer, B.3
  • 49
    • 0028234787 scopus 로고
    • CAG repeat size and clinical presentation in Huntington's disease
    • Ashizawa T, Wong LJC, Richards CS, et al. CAG repeat size and clinical presentation in Huntington's disease. Neurology 1994;44(6):1137-43.
    • (1994) Neurology , vol.44 , Issue.6 , pp. 1137-1143
    • Ashizawa, T.1    Wong, L.J.C.2    Richards, C.S.3
  • 50
    • 0037180419 scopus 로고    scopus 로고
    • Relationship between CAG repeat length and late-stage outcomes in Huntington's disease
    • Marder K, Sandler S, Lechich A, et al. Relationship between CAG repeat length and late-stage outcomes in Huntington's disease. Neurology 2002;59(10): 1622-4.
    • (2002) Neurology , vol.59 , Issue.10 , pp. 1622-1624
    • Marder, K.1    Sandler, S.2    Lechich, A.3
  • 51
    • 84856963229 scopus 로고    scopus 로고
    • Age, CAG repeat length, and clinical progression in Huntington's disease
    • Rosenblatt A, Kumar BV, Mo A, et al. Age, CAG repeat length, and clinical progression in Huntington's disease. Mov Disord 2012;27(2):272-6.
    • (2012) Mov Disord , vol.27 , Issue.2 , pp. 272-276
    • Rosenblatt, A.1    Kumar, B.V.2    Mo, A.3
  • 52
    • 84879486035 scopus 로고    scopus 로고
    • Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS
    • Killoran A, Biglan KM, Jankovic J, et al. Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS. Neurology 2013;80(22): 2022-7.
    • (2013) Neurology , vol.80 , Issue.22 , pp. 2022-2027
    • Killoran, A.1    Biglan, K.M.2    Jankovic, J.3
  • 53
    • 84873463075 scopus 로고    scopus 로고
    • Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease
    • Sathasivam K, Neueder A, Gipson TA, et al. Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease. Proc Natl Acad Sci U S A 2013;110(6):2366-70.
    • (2013) Proc Natl Acad Sci U S A , vol.110 , Issue.6 , pp. 2366-2370
    • Sathasivam, K.1    Neueder, A.2    Gipson, T.A.3
  • 54
    • 77950584656 scopus 로고    scopus 로고
    • Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease
    • Landles C, Sathasivam K, Weiss A, et al. Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease. J Biol Chem 2010;285(12):8808-23.
    • (2010) J Biol Chem , vol.285 , Issue.12 , pp. 8808-8823
    • Landles, C.1    Sathasivam, K.2    Weiss, A.3
  • 55
    • 78650031174 scopus 로고    scopus 로고
    • Huntington's disease: from molecular pathogenesis to clinical treatment
    • Ross CA, Tabrizi SJ. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 2011;10(1):83-98.
    • (2011) Lancet Neurol , vol.10 , Issue.1 , pp. 83-98
    • Ross, C.A.1    Tabrizi, S.J.2
  • 56
    • 0030752709 scopus 로고    scopus 로고
    • Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain
    • DiFiglia M, Sapp E, Chase KO, et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997;277(5334): 1990-3.
    • (1997) Science , vol.277 , Issue.5334 , pp. 1990-1993
    • DiFiglia, M.1    Sapp, E.2    Chase, K.O.3
  • 57
    • 79957748358 scopus 로고    scopus 로고
    • Milestones in Huntington disease
    • Shoulson I, Young AB. Milestones in Huntington disease. Mov Disord 2011;26(6): 1127-33.
    • (2011) Mov Disord , vol.26 , Issue.6 , pp. 1127-1133
    • Shoulson, I.1    Young, A.B.2
  • 58
    • 12944263711 scopus 로고    scopus 로고
    • The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription
    • Steffan JS, Kazantsev A, Spasic-Boskovic O, et al. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci U S A 2000;97(12):6763-8.
    • (2000) Proc Natl Acad Sci U S A , vol.97 , Issue.12 , pp. 6763-6768
    • Steffan, J.S.1    Kazantsev, A.2    Spasic-Boskovic, O.3
  • 59
    • 34547839797 scopus 로고    scopus 로고
    • Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage
    • Kuhn A, Goldstein DR, Hodges A, et al. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum Mol Genet 2007;16(15):1845-61.
    • (2007) Hum Mol Genet , vol.16 , Issue.15 , pp. 1845-1861
    • Kuhn, A.1    Goldstein, D.R.2    Hodges, A.3
  • 60
    • 0032568517 scopus 로고    scopus 로고
    • Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington disease gene
    • Cha JH, Kosinski CM, Kerner JA, et al. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington disease gene. Proc Natl Acad Sci U S A 1998;95(11):6480-5.
    • (1998) Proc Natl Acad Sci U S A , vol.95 , Issue.11 , pp. 6480-6485
    • Cha, J.H.1    Kosinski, C.M.2    Kerner, J.A.3
  • 61
    • 33644783812 scopus 로고    scopus 로고
    • Regional and cellular gene expression changes in human Huntington's disease brain
    • Hodges A, Strand AD, Aragaki AK, et al. Regional and cellular gene expression changes in human Huntington's disease brain.Hum Mol Genet 2006;15(6):965-77.
    • (2006) Hum Mol Genet , vol.15 , Issue.6 , pp. 965-977
    • Hodges, A.1    Strand, A.D.2    Aragaki, A.K.3
  • 62
    • 0035919701 scopus 로고    scopus 로고
    • Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease
    • Zuccato C, Ciammola A, Rigamonti D, et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 2001;293(5529):493-8.
    • (2001) Science , vol.293 , Issue.5529 , pp. 493-498
    • Zuccato, C.1    Ciammola, A.2    Rigamonti, D.3
  • 63
    • 63449090757 scopus 로고    scopus 로고
    • Huntingtin as an essential integrator of intracellular vesicular trafficking
    • Caviston JP, Holzbaur EL. Huntingtin as an essential integrator of intracellular vesicular trafficking. Trends Cell Biol 2009;19(4):147-55.
    • (2009) Trends Cell Biol , vol.19 , Issue.4 , pp. 147-155
    • Caviston, J.P.1    Holzbaur, E.L.2
  • 64
    • 34547193908 scopus 로고    scopus 로고
    • Huntingtin facilitates dynein/dynactinmediated vesicle transport
    • Caviston JP, Ross JL, Antony SM, et al. Huntingtin facilitates dynein/dynactinmediated vesicle transport. Proc Natl Acad Sci U S A 2007;104(24):10045-50.
    • (2007) Proc Natl Acad Sci U S A , vol.104 , Issue.24 , pp. 10045-10050
    • Caviston, J.P.1    Ross, J.L.2    Antony, S.M.3
  • 65
    • 34547807613 scopus 로고    scopus 로고
    • Global changes to the ubiquitin system in Huntington's disease
    • Bennett EJ, Shaler TA, Woodman B, et al. Global changes to the ubiquitin system in Huntington's disease. Nature 2007;448(7154):704-8.
    • (2007) Nature , vol.448 , Issue.7154 , pp. 704-708
    • Bennett, E.J.1    Shaler, T.A.2    Woodman, B.3
  • 66
    • 41549129945 scopus 로고    scopus 로고
    • Impaired ubiquitin-proteasome system activity in the synapses of Huntington's disease mice
    • Wang J, Wang C, Orr A, et al. Impaired ubiquitin-proteasome system activity in the synapses of Huntington's disease mice. J Cell Biol 2008;180(6):1177-89.
    • (2008) J Cell Biol , vol.180 , Issue.6 , pp. 1177-1189
    • Wang, J.1    Wang, C.2    Orr, A.3
  • 67
    • 84892755229 scopus 로고    scopus 로고
    • The regulation of autophagosome dynamics by huntingtin and HAP1 is disrupted by expression of mutant huntingtin, leading to defective cargo degradation
    • Wong YC, Holzbaur EL. The regulation of autophagosome dynamics by huntingtin and HAP1 is disrupted by expression of mutant huntingtin, leading to defective cargo degradation. J Neurosci 2014;34(4):1293-305.
    • (2014) J Neurosci , vol.34 , Issue.4 , pp. 1293-1305
    • Wong, Y.C.1    Holzbaur, E.L.2
  • 68
    • 77951665859 scopus 로고    scopus 로고
    • Cargo recognition failure is responsible for inefficient autophagy in Huntington's disease
    • Martinez-Vicente M, Talloczy Z, Wong E, et al. Cargo recognition failure is responsible for inefficient autophagy in Huntington's disease. Nat Neurosci 2010;13(5): 567-76.
    • (2010) Nat Neurosci , vol.13 , Issue.5 , pp. 567-576
    • Martinez-Vicente, M.1    Talloczy, Z.2    Wong, E.3
  • 69
    • 79952585486 scopus 로고    scopus 로고
    • Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage
    • Shirendeb U, Reddy AP, Manczak M, et al. Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage. Hum Mol Genet 2011;20(7):1438-55.
    • (2011) Hum Mol Genet , vol.20 , Issue.7 , pp. 1438-1455
    • Shirendeb, U.1    Reddy, A.P.2    Manczak, M.3
  • 70
    • 33750437278 scopus 로고    scopus 로고
    • Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1 alpha in Huntington's disease neurodegeneration
    • Weydt P, Pineda VV, Torrence AE, et al. Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1 alpha in Huntington's disease neurodegeneration. Cell Metab 2006;4(5):349-62.
    • (2006) Cell Metab , vol.4 , Issue.5 , pp. 349-362
    • Weydt, P.1    Pineda, V.V.2    Torrence, A.E.3
  • 71
    • 33749042331 scopus 로고    scopus 로고
    • Transcriptional repression of PGC-alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration
    • Cui L, Jeong H, Borovecki F, et al. Transcriptional repression of PGC-alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 2006;127(1):59-69.
    • (2006) Cell , vol.127 , Issue.1 , pp. 59-69
    • Cui, L.1    Jeong, H.2    Borovecki, F.3
  • 72
    • 84855481293 scopus 로고    scopus 로고
    • Early alterations of brain cellular energy homeostasis in Huntington disease models
    • Mochel F, Durant B, Meng X, et al. Early alterations of brain cellular energy homeostasis in Huntington disease models. J Biol Chem 2012;287(2):1361-70.
    • (2012) J Biol Chem , vol.287 , Issue.2 , pp. 1361-1370
    • Mochel, F.1    Durant, B.2    Meng, X.3
  • 73
    • 0030919567 scopus 로고    scopus 로고
    • Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia
    • Browne SE, Bowling AC, MacGarvey U, et al. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann Neurol 1997;41(5):646-53.
    • (1997) Ann Neurol , vol.41 , Issue.5 , pp. 646-653
    • Browne, S.E.1    Bowling, A.C.2    MacGarvey, U.3
  • 74
    • 0031044805 scopus 로고    scopus 로고
    • Energy metabolism defects in Huntington's disease and effects of coenzyme Q(10)
    • Koroshetz WJ, Jenkins BG, Rosen BR, et al. Energy metabolism defects in Huntington's disease and effects of coenzyme Q(10). Ann Neurol 1997;41(2):160-5.
    • (1997) Ann Neurol , vol.41 , Issue.2 , pp. 160-165
    • Koroshetz, W.J.1    Jenkins, B.G.2    Rosen, B.R.3
  • 75
    • 0032971311 scopus 로고    scopus 로고
    • Subtype-specific enhancement of NMDA receptor currents by mutant huntingtin
    • Chen N, Luo T, Wellington C, et al. Subtype-specific enhancement of NMDA receptor currents by mutant huntingtin. J Neurochem 1999;72(5):1890-8.
    • (1999) J Neurochem , vol.72 , Issue.5 , pp. 1890-1898
    • Chen, N.1    Luo, T.2    Wellington, C.3
  • 76
    • 0035154912 scopus 로고    scopus 로고
    • Mutant huntingtin enhances excitotoxic cell death
    • Zeron M, Chen N, Moshaver A, et al. Mutant huntingtin enhances excitotoxic cell death. Mol Cell Neurosci 2001;17(1):41-53.
    • (2001) Mol Cell Neurosci , vol.17 , Issue.1 , pp. 41-53
    • Zeron, M.1    Chen, N.2    Moshaver, A.3
  • 77
    • 14044264256 scopus 로고    scopus 로고
    • Disturbed Ca21 signaling and apoptosis of medium spiny neurons in Huntington's disease
    • Tang T, Slow E, Lupu V, et al. Disturbed Ca21 signaling and apoptosis of medium spiny neurons in Huntington's disease. Proc Natl Acad Sci U S A 2005;102(7): 2602-7.
    • (2005) Proc Natl Acad Sci U S A , vol.102 , Issue.7 , pp. 2602-2607
    • Tang, T.1    Slow, E.2    Lupu, V.3
  • 78
    • 58349114259 scopus 로고    scopus 로고
    • Atypical antipsychotic drugs and the risk of sudden cardiac death
    • Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009;360(3):225-35.
    • (2009) N Engl J Med , vol.360 , Issue.3 , pp. 225-235
    • Ray, W.A.1    Chung, C.P.2    Murray, K.T.3
  • 79
    • 33645798913 scopus 로고    scopus 로고
    • Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial
    • Marshall FJ, Walker F, Frank S, et al. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 2006;66(3):366-72.
    • (2006) Neurology , vol.66 , Issue.3 , pp. 366-372
    • Marshall, F.J.1    Walker, F.2    Frank, S.3
  • 80
    • 0037056392 scopus 로고    scopus 로고
    • Huntington's disease - a randomized, controlled trial using the NMDA-antagonist amantadine
    • Metman LV, Morris MJ, Farmer C, et al. Huntington's disease - a randomized, controlled trial using the NMDA-antagonist amantadine. Neurology 2002;59(5): 694-9.
    • (2002) Neurology , vol.59 , Issue.5 , pp. 694-699
    • Metman, L.V.1    Morris, M.J.2    Farmer, C.3
  • 81
    • 0038375825 scopus 로고    scopus 로고
    • A randomized trial of amantadine in Huntington disease
    • O'Suilleabhain P, Dewey RB. A randomized trial of amantadine in Huntington disease. Arch Neurol 2003;60(7):996-8.
    • (2003) Arch Neurol , vol.60 , Issue.7 , pp. 996-998
    • O'Suilleabhain, P.1    Dewey, R.B.2
  • 82
    • 0019254352 scopus 로고
    • Seven cases of huntington's disease in childhood and levodopa induced improvement in the hypokinetic - Rigid form
    • Jongen PJ, Renier WO, Gabreels FJ. Seven cases of huntington's disease in childhood and levodopa induced improvement in the hypokinetic - Rigid form. Clin Neurol Neurosurg 1980;82(4):251-61.
    • (1980) Clin Neurol Neurosurg , vol.82 , Issue.4 , pp. 251-261
    • Jongen, P.J.1    Renier, W.O.2    Gabreels, F.J.3
  • 83
    • 33645216173 scopus 로고    scopus 로고
    • Dose-dependent improvement of myoclonic hyperkinesia due to valproic acid in eight Huntington's disease patients: a case series
    • Saft C, Lauter T, Kraus PH, et al. Dose-dependent improvement of myoclonic hyperkinesia due to valproic acid in eight Huntington's disease patients: a case series. BMC Neurol 2006;6:11.
    • (2006) BMC Neurol , vol.6 , pp. 11
    • Saft, C.1    Lauter, T.2    Kraus, P.H.3
  • 84
    • 84860385532 scopus 로고    scopus 로고
    • An evidence-based approach in the treatment of Huntington's disease
    • Mestre TA, Ferreira JJ. An evidence-based approach in the treatment of Huntington's disease. Parkinsonism Relat Disord 2012;18(4):316-20.
    • (2012) Parkinsonism Relat Disord , vol.18 , Issue.4 , pp. 316-320
    • Mestre, T.A.1    Ferreira, J.J.2
  • 85
    • 85030407656 scopus 로고    scopus 로고
    • ACTION-HD: a randomized, doubleblind, placebo-controlled prospective crossover trial investigating the efficacy and safety of bupropion in Huntington's disease
    • Gelderblom H, Fischer W, McLean T, et al. ACTION-HD: a randomized, doubleblind, placebo-controlled prospective crossover trial investigating the efficacy and safety of bupropion in Huntington's disease. Neurotherapeutics 2013;10(1): 180-1.
    • (2013) Neurotherapeutics , vol.10 , Issue.1 , pp. 180-181
    • Gelderblom, H.1    Fischer, W.2    McLean, T.3
  • 86
    • 4544335687 scopus 로고    scopus 로고
    • The N-methyl-D-aspartate antagonist memantine retards progression of Huntington's disease
    • Beister A, Kraus P, Kuhn W, et al. The N-methyl-D-aspartate antagonist memantine retards progression of Huntington's disease. J Neural Transm Suppl 2004;(68):117-22.
    • (2004) J Neural Transm Suppl , vol.68 , pp. 117-122
    • Beister, A.1    Kraus, P.2    Kuhn, W.3
  • 87
    • 33846815309 scopus 로고    scopus 로고
    • Two years' follow-up of rivastigmine treatment in Huntington disease
    • de Tommaso M, Difruscolo O, Sciruicchio V, et al. Two years' follow-up of rivastigmine treatment in Huntington disease. Clin Neuropharmacol 2007;30(1):43-6.
    • (2007) Clin Neuropharmacol , vol.30 , Issue.1 , pp. 43-46
    • de Tommaso, M.1    Difruscolo, O.2    Sciruicchio, V.3
  • 88
    • 33749861388 scopus 로고    scopus 로고
    • Effect of donepezil on motor and cognitive function in Huntington disease
    • Cubo E, Shannon KM, Tracy D, et al. Effect of donepezil on motor and cognitive function in Huntington disease. Neurology 2006;67(7):1268-71.
    • (2006) Neurology , vol.67 , Issue.7 , pp. 1268-1271
    • Cubo, E.1    Shannon, K.M.2    Tracy, D.3
  • 89
    • 46449134291 scopus 로고    scopus 로고
    • Long-term follow-up of Huntington disease treated by bilateral deep brain stimulation of the internal globus pallidus
    • Biolsi B, Cif L, El Fertit H, et al. Long-term follow-up of Huntington disease treated by bilateral deep brain stimulation of the internal globus pallidus. J Neurosurg 2008;109(1):130-2.
    • (2008) J Neurosurg , vol.109 , Issue.1 , pp. 130-132
    • Biolsi, B.1    Cif, L.2    El Fertit, H.3
  • 90
    • 79951814028 scopus 로고    scopus 로고
    • Long-term follow-up of pallidal deep brain stimulation in two cases of Huntington's disease
    • Kang GA, Heath S, Rothlind J, et al. Long-term follow-up of pallidal deep brain stimulation in two cases of Huntington's disease. J Neurol Neurosurg Psychiatr 2011;82(3):272-7.
    • (2011) J Neurol Neurosurg Psychiatr , vol.82 , Issue.3 , pp. 272-277
    • Kang, G.A.1    Heath, S.2    Rothlind, J.3
  • 91
    • 33847657635 scopus 로고    scopus 로고
    • Comprehensive care in Huntington's disease - a physician's perspective
    • Nance MA. Comprehensive care in Huntington's disease - a physician's perspective. Brain Res Bull 2007;72(2-3):175-8.
    • (2007) Brain Res Bull , vol.72 , Issue.2-3 , pp. 175-178
    • Nance, M.A.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.